These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 35508762)

  • 21. Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping.
    Loureiro AI; Fernandes-Lopes C; Bonifácio MJ; Sousa F; Kiss LE; Soares-da-Silva P
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00891. PubMed ID: 34939338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone.
    Jenner P; Rocha JF; Ferreira JJ; Rascol O; Soares-da-Silva P
    Expert Rev Neurother; 2021 Sep; 21(9):1019-1033. PubMed ID: 34525893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
    Surapaneni S; Yerramilli U; Bai A; Dalvie D; Brooks J; Wang X; Selkirk JV; Yan YG; Zhang P; Hargreaves R; Kumar G; Palmisano M; Tran JQ
    Drug Metab Dispos; 2021 May; 49(5):405-419. PubMed ID: 33674268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mercapturic acid pathway.
    Hanna PE; Anders MW
    Crit Rev Toxicol; 2019 Nov; 49(10):819-929. PubMed ID: 31944156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets.
    Alexander SPH; Kelly E; Mathie A; Peters JA; Veale EL; Armstrong JF; Faccenda E; Harding SD; Pawson AJ; Sharman JL; Southan C; Buneman OP; Cidlowski JA; Christopoulos A; Davenport AP; Fabbro D; Spedding M; Striessnig J; Davies JA;
    Br J Pharmacol; 2019 Dec; 176 Suppl 1(Suppl 1):S1-S20. PubMed ID: 31710719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes.
    Alexander SPH; Fabbro D; Kelly E; Mathie A; Peters JA; Veale EL; Armstrong JF; Faccenda E; Harding SD; Pawson AJ; Sharman JL; Southan C; Davies JA;
    Br J Pharmacol; 2019 Dec; 176 Suppl 1(Suppl 1):S297-S396. PubMed ID: 31710714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opicapone for the treatment of Parkinson's disease: an update.
    Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
    Expert Opin Pharmacother; 2019 Dec; 20(18):2201-2207. PubMed ID: 31670988
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety Profile of Opicapone in the Management of Parkinson's Disease.
    Lees A; Ferreira JJ; Rocha JF; Rascol O; Poewe W; Gama H; Soares-da-Silva P
    J Parkinsons Dis; 2019; 9(4):733-740. PubMed ID: 31498127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping human microbiome drug metabolism by gut bacteria and their genes.
    Zimmermann M; Zimmermann-Kogadeeva M; Wegmann R; Goodman AL
    Nature; 2019 Jun; 570(7762):462-467. PubMed ID: 31158845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
    Cabreira V; Soares-da-Silva P; Massano J
    Drugs; 2019 Apr; 79(6):593-608. PubMed ID: 30905034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions.
    Clarke G; Sandhu KV; Griffin BT; Dinan TG; Cryan JF; Hyland NP
    Pharmacol Rev; 2019 Apr; 71(2):198-224. PubMed ID: 30890566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P
    Eur J Neurol; 2019 Jul; 26(7):953-960. PubMed ID: 30681754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
    Fabbri M; Ferreira JJ; Lees A; Stocchi F; Poewe W; Tolosa E; Rascol O
    Mov Disord; 2018 Oct; 33(10):1528-1539. PubMed ID: 30264443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions.
    Makino C; Watanabe A; Deguchi T; Shiozawa H; Schreck I; Rozehnal V; Ishizuka T; Watanabe N; Ando O; Murayama N; Yamazaki H
    Xenobiotica; 2019 Aug; 49(8):961-969. PubMed ID: 30124356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.
    Fackrell R; Carroll CB; Grosset DG; Mohamed B; Reddy P; Parry M; Chaudhuri KR; Foltynie T
    Neurodegener Dis Manag; 2018 Oct; 8(5):349-360. PubMed ID: 29975112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.
    Ferreira JJ; Lees AJ; Poewe W; Rascol O; Rocha JF; Keller B; Soares-da-Silva P
    Neurology; 2018 May; 90(21):e1849-e1857. PubMed ID: 29695590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The launch of opicapone for Parkinson's disease: negatives versus positives.
    Castro Caldas A; Teodoro T; Ferreira JJ
    Expert Opin Drug Saf; 2018 Mar; 17(3):331-337. PubMed ID: 29415596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?
    Swanson HI
    Drug Metab Dispos; 2015 Oct; 43(10):1499-504. PubMed ID: 26261284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
    Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
    Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.
    Kiss LE; Soares-da-Silva P
    J Med Chem; 2014 Nov; 57(21):8692-717. PubMed ID: 25080080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.